Patent · US Active

SMAC peptidometics useful as IAP inhibitors

US8546336B2 · kind B2 · utility

12Cited by

10References

3Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Zhuoliang Chen · Cambridge, US
Mark G. Charest · Montgomery, US
Christine Hiu-Tung Chen · Waltham, US
Miao Dai · Shanghai, CN
Feng He · Nanhu, CN
Huangshu Lei · Ann Arbor, US
Ly Pham · Ann Arbor, US
Sushil Sharma · East Hanover, US
Christopher Sean Straub · Cambridge, US
Run-Ming David Wang · Cambridge, US
Fan Yang · Brookline, US
Leigh Zawel · Bowie, US

Key dates

Filing date	Sep 7, 2012
Grant date	Oct 1, 2013
Priority date	—
Expiry date	Sep 7, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K5/06191
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to a compound of the formula:or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.